BCL2L1 and colorectal carcinoma: Out of these, BclXL was able to differentiate high and low risk CRC patients, on the basis of mean (HR = 7.19, p-value = 0.0004) [14] and median (HR = 20.81, p = 0.0030) cutoffs, thus achieving maximum differentiation.